1. MARKETS
  2. SECTOR : BANKING AND FINANCE
  3. INDUSTRY : FINANCIAL CONGLOMERATES
  4. NKGEN BIOTECH INC

NKGen Biotech Inc

XNAS: NKGN

Download real time

0.17 -0.01 (-5.56%)

92.24% Fall from 52W High

118.7K XNAS Volume

XNAS 01 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
5S
12W
1O
2T
7.7

Market Cap

Low in industry
-0.2

PE TTM

Negative PE TTM
0

PEG TTM

-0.1

Price to Book

Negative Price to Book
-0.4

Beta 1Year

Very Low volatility


Insider Trading disclosures for NKGen Biotech Inc

The latest disclosure was made by James A. Graf in NKGen Biotech Inc where a trade of 500,000 Stock Option (right to buy) done was reported to US exchanges on Dec. 6, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
James A. Graf Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2024 500,000 500,000 - - Stock Option (right to buy)
Kathleen D. Scott Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2024 500,000 500,000 - - Stock Option (right to buy)
Kathleen D. Scott Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2024 300,000 300,000 - - Stock Option (right to buy)
Paul Y. Song Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2024 2,000,000 2,000,000 - - Stock Option (right to buy)
Michael Klowden Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2024 500,000 500,000 - - Stock Option (right to buy)
Michael Klowden Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2024 300,000 300,000 - - Stock Option (right to buy)
Marco Gottardis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 May 2024 300,000 16,667 - - Stock Option (right to buy)
Paul Song Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2024 1,260,000 1,260,000 - - Stock Option (right to buy)
Michael Klowden Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2024 300,000 300,000 - - Stock Option (right to buy)
Gagnon Pierre Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2024 360,000 360,000 - - Stock Option (right to buy
D. Scott Kathleen Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2024 300,000 300,000 - - Stock Option (right to buy)
Kim Yong-man CSO and CIO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Feb 2024 75,000 75,000 - - Stock Option (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters